The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The orphan nuclear receptor TR3 (NR41A and Nur77) is overexpressed in most lung cancer patients and is a negative prognostic factor for patient survival. The function of TR3 was investigated in non-small-cell lung cancer A549 and H460 cells, and knockdown of TR3 by RNA interference (siTR3) inhibited cancer cell growth and induced apoptosis. The prosurvival activity of TR3 was due, in part, to formation of a p300/TR3/ specificity protein 1 complex bound to GC-rich promoter regions of survivin and other Sp-regulated genes (mechanism 1). However, in p53 wild-type A549 and H460 cells, siTR3 inhibited the mTORC1 pathway, and this was due to activation of p53 and induction of the p53-responsive gene sestrin 2, which subsequently activated the mTORC1 inhibitor AMP-activated protein kinase α (AMPKα) (mechanism 2). This demonstrates that the pro-oncogenic activity of TR3 in lung cancer cells was due to inhibition of p53 and activation of mTORC1. 1,1-Bis(3’-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) is a recently discovered inhibitor of TR3, which mimics the effects of siTR3. DIM-C-pPhOH inhibited growth and induced apoptosis in lung cancer cells and lung tumors in murine orthotopic and metastatic models, and this was accompanied by decreased expression of survivin and inhibition of mTORC1 signaling, demonstrating that inactivators of TR3 represent a novel class of mTORC1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“…has become an increasingly important target for anticancer drugs such as rapamycin because of its central role in regulating multiple downstream pro-oncogenic factors (Bjornsti and Houghton, 2004; Hay and Sonenberg, 2004; Shaw and Cantley, 2006; Guertin and Sabatini, 2007; Yang and Guan, 2007).”
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 3×
“A recent report showed that regulation of mTORC1 signaling by p53 is through p53-dependent activation of sestrins which, in turn, activate AMPK α (Budanov and Karin, 2008; Lee et al ., 2010a).”
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies
Lee, J. H., Budanov, A. V., Park, E. J., Birse, R., Kim, T. E., Perkins, G. A., Ocorr, K., Ellisman, M. H., Bodmer, R., Bier, E., et al. (2010) · Science · doi:10.1126/science.1182228 · Cited by 570
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400 · cited 1×
“The phosphorylated forms of 4E-BP1 and p70S6K are key downstream targets of mTORC1 that regulate initiation and translation of multiple genes, such as cyclin D1 and cyclin A, that are critical for normal cell growth, and in a cancer context many of the the 4E-BP1- and p70S6K-regulated genes are prooncogenic (Hay and S…”
Cited by
Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis
Palumbo-Zerr, K., Zerr, P., Distler, A., Fliehr, J., Mancuso, R., Huang, J., Mielenz, D., Tomcik, M., Fürnrohr, B. G., Scholtysek, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3777 · Cited by 342
Sestrins Orchestrate Cellular Metabolism to Attenuate Aging
Lee, J. H., Budanov, A. V., & Karin, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.018 · Cited by 338
The role of tumor suppressor p53 in the antioxidant defense and metabolism
Budanov, A. V. (2014) · Subcellular Biochemistry · doi:10.1007/978-94-017-9211-0_18 · Cited by 157
Rodríguez-Calvo, R., Tajes, M., & Vázquez-Carrera, M. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1279146 · Cited by 117
Zhao, B., Shah, P., Budanov, A. V., Qiang, L., Ming, M., Aplin, A., Sims, D. M., & He, Y.-Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595397 · Cited by 61
Key Functions and Therapeutic Prospects of Nur77 in Inflammation Related Lung Diseases
Banno, A., Lakshmi, S. P., Reddy, A. T., Kim, S. C., & Reddy, R. C. (2019) · The American Journal of Pathology · doi:10.1016/j.ajpath.2018.10.002 · Cited by 53
“In addition, Nur77 can modulate target gene expression independently of DNA binding through its effects on other proteins, such as NF-kB family members(3,14) and the zinc finger transcription factor specificity protein 1.(15)”
BackgroundMohankumar, K., Lee, J., Wu, C. S., Sun, Y., & Safe, S. (2018) · Endocrinology · doi:10.1210/en.2017-03049 · Cited by 24
Self-citation
Metadata
- Authors
- Lee, S.-O., Andey, T., Jin, U.-H., Kim, K., Sachdeva, M., & Safe, S.
- Venue
- Oncogene
- Published
- 2011-11-14
- Volume
- 31
- Issue
- 27
- Pages
- 3265-3276
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2073801259
- Cited by
- 122
- References
- 6
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.